Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
2d
Zacks.com on MSNVKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results